Cambridge Investment Research Advisors’s Minerva Neurosciences NERV Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,738	Closed	-$12K	–	3162
2022 Q1	$12K	Hold	1,738	–	–	﹤0.01%	3136
2021 Q4	$11K	Sell	1,738 -187	-10%	-$1.76K	﹤0.01%	3148
2021 Q3	$27K	Hold	1,925	–	–	﹤0.01%	3049
2021 Q2	$36K	Sell	1,925 -188	-9%	-$4.05K	﹤0.01%	3041
2021 Q1	$49K	Hold	2,113	–	–	﹤0.01%	2806
2020 Q4	$40K	Sell	2,113 -325	-13%	-$8.19K	﹤0.01%	2659
2020 Q3	$62K	Hold	2,438	–	–	﹤0.01%	2433
2020 Q2	$70K	Buy	2,438 +63	+3%	+$3.69K	﹤0.01%	2357
2020 Q1	$114K	Sell	2,375 -250	-10%	-$15.1K	﹤0.01%	2089
2019 Q4	$149K	Hold	2,625	–	–	﹤0.01%	2269
2019 Q3	$163K	Buy	+2,625	New	+$149K	﹤0.01%	2166

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cambridge Investment Research Advisors's NERV Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of Minerva Neurosciences (NERV) in Q2 2022, closing a stake of 1,738 shares — an estimated $12K sold.

Cambridge Investment Research Advisors first reported a position in NERV in Q3 2019 and held it in 11 quarters. The position peaked at $163K in Q3 2019. 23 funds tracked by Wall St. Rank hold NERV as of Q2 2022.

Cambridge Investment Research Advisors reported no remaining Minerva Neurosciences position as of Q2 2022 after selling out during the quarter.
Cambridge Investment Research Advisors sold 1,738 Minerva Neurosciences shares in Q2 2022, an estimated $12K.
Cambridge Investment Research Advisors first reported a position in Minerva Neurosciences in Q3 2019 and held it in 11 quarters.
Cambridge Investment Research Advisors's Minerva Neurosciences position peaked at $163K in Q3 2019.
23 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.